Stephen Parmley, Ph.D.Vice President, Molecular Biology & Protein Science at AnaptysBio
Stephen Parmley is Vice President of Molecular Biology, Target Biology and Protein Sciences at AnaptysBio, a clinical-stage biotechnology company developing first-in-class antibodies to treat patients with inflammatory diseases and cancers. He has more than 30 years of experience in protein engineering, high throughput screening, and therapeutic biologics discovery. Previously, Stephen was Director of Molecular Biology at Maxygen and Perseid Therapeutics were he applied phage display and directed molecular evolution technologies to the generation of novel therapeutic proteins for inflammatory diseases. Prior to his move into the biotechnology industry, he was a post-doctoral fellow in infectious diseases with Jack S. Remington at Stanford University and principal investigator at the Palo Alto Medical Foundation Research Institute studying the life cycle and host immunological responses to opportunistic protozoan pathogens. He received a B.S. in Biological Sciences from the University of Kansas and a Ph.D. in Biological Sciences at the University of Missouri in the laboratory of Nobel Laureate George P. Smith where Stephen developed the earliest phage display vectors and pioneered the time-honored methods for recursive affinity selection of phage libraries that are still fundamental to the technology.